Request Demo
Last update 09 Dec 2025
Puzolcabtagene Autoleucel
Last update 09 Dec 2025
Overview
Basic Info
Drug Type CAR-T |
Synonyms Anti-CD19-Car T cell therapy, PCAR 19B, pCAR-19B(Chongqing Precision Biotechnology) + [3] |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (04 Nov 2025), |
RegulationPriority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China) |
Login to view timeline
Related
6
Clinical Trials associated with Puzolcabtagene AutoleucelCTR20241718
靶向CD19嵌合抗原受体T淋巴细胞（pCAR-19B）自体回输制剂治疗CD19阳性复发/难治性B细胞急性淋巴细胞白血病（22～70周岁）的Ⅱ期临床研究
[Translation] Phase II clinical study of autologous infusion of CD19-targeted chimeric antigen receptor T lymphocytes (pCAR-19B) in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia (22-70 years old)
NCT06222853
A Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor T Cell Injection Targeting CD19 Gene in the Treatment of Refractory Systemic Lupus Erythematosus
NCT05334823
A Phase II Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL
100 Clinical Results associated with Puzolcabtagene Autoleucel
Login to view more data
100 Translational Medicine associated with Puzolcabtagene Autoleucel
Login to view more data
100 Patents (Medical) associated with Puzolcabtagene Autoleucel
Login to view more data
1
Literatures (Medical) associated with Puzolcabtagene AutoleucelBMC Pediatrics
Frontline therapy combining with intrathecal dexamethasone effectively alleviate immune effector cell-associated neurotoxicity syndrome in pediatric relapsed B-ALL receiving pCAR-19B-cases report
Article
Author: Cao, Lu ; Hu, Shaoyan ; Zhu, Ruixin ; Bai, Zhengjiang ; Zhou, Libing ; Chen, Hongmei ; Wu, Shuiyan ; Wei, Zhequn ; Zhou, Min
100 Deals associated with Puzolcabtagene Autoleucel
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| CD19-positive B-cell acute lymphoblastic leukemia | China | 04 Nov 2025 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Refractory Adult Acute Lymphoblastic Leukemia | Phase 2 | China | 26 Jan 2022 | |
| Systemic Lupus Erythematosus | Phase 1 | China | 10 Feb 2024 | |
| CD19 positive Non-Hodgkin Lymphoma | Phase 1 | China | 06 Sep 2021 | |
| Recurrent Childhood Acute Lymphoblastic Leukemia | Phase 1 | China | 05 Nov 2019 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 22 | qmpnqxuwpg(pfpsfwfwen) = qmsrkrnhhf vmwvvcnukw (dtyzsxqvhp ) View more | Positive | 08 Nov 2025 | |||
NCT05334823 (ASH2024) Manual  | Phase 2 | CD19-positive B-cell acute lymphoblastic leukemia CD19 Positive | 64 | rbjedleepo(hpqzzkaycg) = lvxxrirzik ksudjwcach (dfoezfkwwk ) View more | Positive | 09 Dec 2024 | |
Phase 1 | 11 | ibhwmxsfuz(ylmgkrabdu) = myeaucrvwz momhpyxpqq (lpdvdaoooy ) | Positive | 26 Oct 2024 | |||
Phase 1 | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma CD19 Positive | 9 | lpuspovyrg(acmlshaxdo) = feuhovjzhf cwkekcqqnf (vtxwtrehli ) View more | Positive | 15 Nov 2022 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free